Cutting-edge biotech builds on best-in-class software to
automate R&D workflows for designing novel drug candidates
using machine learning approaches
BASEL,
Switzerland, July 17,
2024 /PRNewswire-PRWeb/ -- Genedata, the leading
provider of enterprise software solutions for biopharmaceutical
R&D, today announced that BioCopy, a research-based
biotechnology company and innovator in combining artificial
intelligence with end-to-end automated protein engineering to
generate safe and effective cancer drugs, has chosen Genedata to
streamline the discovery and development of next-generation
multi-specific biotherapeutics for the treatment of cancer.
Our end-to-end automated engineering lab
produces massive amounts of complex data unmatched in the industry
that Genedata captures and structures into high-quality and
contextualized information to feed into our AI platform. Jörg
Birkenfeld, Ph.D., CSO of BioCopy
"We brought in Genedata as our data backbone to ensure all
information across projects and groups is analyzed in a central
platform so that we can speed up the development of cancer drugs,"
said Jörg Birkenfeld, Ph.D., CSO of BioCopy. "Our end-to-end
automated engineering lab produces massive amounts of complex data
unmatched in the industry that Genedata captures and structures
into high-quality and contextualized information to feed into our
AI platform. This is critical for accelerating our research and
provides the basis for data-driven design of innovative drug
candidates."
BioCopy uses an AI-powered, end-to-end automated platform that
enables the development of highly efficient and safe multi-specific
biotherapeutics. Using their proprietary technology ValidaTe,
BioCopy performs large-scale analyses of the interaction between a
multitude of cancer cell markers and potential biotherapeutics.
BioCopy's automated engineering lab provides the capacity to
combine various functionally distinct molecular components into a
single drug candidate based on a building-block assembly method. It
also analyzes up to 25,000 novel candidates in parallel for
multiple attributes that are critical for the developability of the
molecules. This contributes significantly to an accelerated
time-to-market for biotherapeutic drug candidates.
The volume and complexity of BioCopy's R&D data led them to
choose Genedata Biologics® and Genedata Screener® as their
enterprise digital solution to streamline increasingly
sophisticated multi-specific antibody engineering workflows.
Genedata Biologics is used for designing, registering, tracking,
and analyzing candidate molecules, including expression,
purification and assay analytics. The platform is fully integrated
with BioCopy's laboratory instruments and IT infrastructure to
ensure full data traceability and integrity.
"We are pleased that BioCopy builds their AI-centered R&D on
Genedata to make their R&D faster and more efficient, helping
them deliver cutting-edge therapeutics to patients sooner," said
Othmar Pfannes, Ph.D., CEO of
Genedata. "Genedata will continue to invest in our foundational
platform for AI, providing a solid basis for AI/ML-based drug
discovery."
About BioCopy
BioCopy is a Swiss-German biotech company with headquarters in
Basel and a state-of-the-art
R&D facility in Emmendingen, Germany. The company focuses on drastically
accelerating the development of safe and effective next-generation
cancer drugs to improve the chance of a cure significantly. BioCopy
combines artificial intelligence with its automated end-to-end
engineering platform to create biotherapeutics with unrivalled
efficacy and safety that are transforming the R&D process in
today's pharmaceutical industry. The BioCopy platform generates
data sets of high quality and quantity currently unmatched in the
industry that are essential to leverage the potential of AI. This
synergy reduces the research and development time of
next-generation biotherapeutics from approximately three years to
12 months. It will save valuable time in the fight against cancer
and significantly reduce the cost of cancer therapeutics.
In the long term, BioCopy will expand its efforts beyond cancer
and develop biotherapeutics for immunological and neurological
diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and
industry insider in the pharmaceutical and biotechnology industry,
not least through his time as CEO of STADA Arzneimittel AG.
http://www.biocopy.com
LinkedIn
About Genedata
Genedata transforms data into intelligence with innovative software
solutions that incorporate extensive biopharma R&D domain
knowledge. Multinational biopharmaceutical organizations and
cutting-edge biotechs around the globe rely on Genedata to
digitalize and automate data-rich and complex R&D processes.
From early discovery all the way to the clinic, Genedata solutions
help maximize the ROI in R&D expenditure. Founded in 1997,
Genedata is headquartered in Basel,
Switzerland with additional offices in Boston, London, Munich, San
Francisco, Singapore, and
Tokyo.
http://www.genedata.com
LinkedIn | X | YouTube
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Dr. Claudia Duppé
BioCopy
Director Communications
press@biocopy.com
Disclaimer
The statements in this press release that relate to future plans,
events or performance are forward-looking statements that involve
risks and uncertainties, including risks associated with
uncertainties related to contract cancellations, developing risks,
competitive factors, uncertainties pertaining to customer orders,
demand for products and services, development of markets for the
Company's products and services. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to
release publicly the result of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
All product and service names mentioned are the trademarks of
their respective companies.
Media Contact
Allison Kurz, Genedata, +41 61
511 84 00, pr@genedata.com, www.genedata.com
View original content to download
multimedia:https://www.prweb.com/releases/biocopy-chooses-genedata-for-ai-powered-multispecific-antibody-discovery-302195831.html
SOURCE Genedata